LONDON - Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc., (Hikma) offered the following comments on the unanimous decision issued on June 4, 2026, by the Supreme Court of the United States effectively ending Amarin’s patent infringement litigation against the company, according to the official website of Hikma. 

“Hikma has long fought for patients and their access to safe, high-quality, and affordable medicines,” said Sam Park, General Counsel, Hikma. “We welcome the United States Supreme Court’s decision, which allows us to continue providing millions of American patients with generic medicines that improve health and save lives.”

“Our more than 2,300 US employees and their Hikma colleagues around the world remain hard at work developing, manufacturing and distributing essential generic medicines that have become a cornerstone of the US health care system and that serve the needs of hospitals, doctors, pharmacists and patients nationwide,” said Mr. Park. 
 
The dispute between the companies involved Hikma’s icosapent ethyl, a medicine made from purified fish oil for people with severe hypertriglyceridemia. Hikma obtained FDA approval and in 2020 launched a generic version of Amarin’s branded icosapent, Vascepa® covering only the non-patented use of the medicine. This is known in the industry as a ‘skinny label.’  The law enabling skinny labelling is designed to bring cheaper medications to patients more quickly.

Amarin sued Hikma, wrongly alleging that Hikma was marketing the generic icosapent ethyl for both the patented and non-patented uses. A US district court dismissed Amarin’s suit, but a federal appeals court overturned that ruling and allowed Amarin’s case to proceed. Hikma then appealed to the Supreme Court.

“Hikma took this fight to the Supreme Court to ensure patients have ongoing access to generic medicines, especially those medicines that have appropriately carved out patented indications,” continued Mr. Park. “Amarin’s lawsuit sought to limit legitimate generic competition, despite long-established legal frameworks governing generic medicines in the US. We are very pleased the US Supreme Court has ended this litigation, which will have a beneficial impact on all Americans.”

Hikma also thanks the many organizations and individuals who supported its position before the Court.